Tag: drug

2 men held in plush Mohali society for IPL betting racket, drug dealing

a group of people wearing military uniforms: Mobile phones and other items seized during police raids at Homeland Heights in Mohali. (Gurminder Singh/HT)

© Provided by Hindustan Times
Mobile phones and other items seized during police raids at Homeland Heights in Mohali. (Gurminder Singh/HT)

Two men from Haryana were arrested at the tony Homeland Heights in Sector 70 late on Saturday evening in police raids for running a betting racket involving Indian Premier League (IPL) matches and alleged smuggling of drugs, including heroin, while two others managed to escape from the spot.

Police recovered 15 mobile phones, laptops and 570 gram heroin from their possession.

The men who were arrested were identified as Vipin of Patel Nagar in Hisar and Rakesh Manchanda from Faridabad. Tarush Dhawan of Kaithal and Malkit Singh of Kila Lal village in Gurdaspur district were absconding.

Police raided the Homeland Heights apartment after receiving a tip-off that online betting was taking place there. Rajiv Kumar, station house officer, Mataur police station and Gursher Singh Sandhu, DSP (City1), led the police team and nabbed the suspects, said Harwinder Singh Virk, superintendent of police (City), while addressing mediapersons on Sunday.

“The suspects were also involved in large scale drug smuggling,” said Virk.

Investigations revealed that the men had been living in the apartment for two months and had placed bets on around 35 cricket matches so far. They used to stake around Rs 4 lakh to Rs 5 lakh on a single match and carried out transactions through Google Pay and Paytm, said Satinder Singh, senior superintendent of police.

Searches are being conducted for the men who were absconding, he added.

A case under Sections 420 of the Indian Penal Code, 13, 3/67 of the Gambling Act and 21, 29-61-85 of the Narcotic Drugs and Psychotropic Substances Act was registered against the suspects at the Mataur police station.

Sign on to read the HT ePaper epaper.hindustantimes.com

Source Article

Continue reading

Continued Government Failures on Drug Pricing

In an effort to lower U.S. drug prices, President Trump has signed an executive order tying Medicare’s payments for drugs to the prices paid in other nations. Under this “most favored nation” rule, Medicare’s payments under Part B, which covers medicines typically administered in doctors’ offices, along with Part D, which covers self-administered medicines mostly obtained from pharmacies, could not exceed the lowest price paid in any developed country.

Trump’s gut instinct on drug prices is right: They are too high in the United States and too low abroad, but his advisers led him down the wrong path in addressing this disparity. The pricing disparity stems from government failures preventing price competition, among sellers here and buyers abroad. And the proposed “solution” adds additional layers of government controls that would do little to lower U.S. prices and could actually increase the foreign freeriding that understandably riles the president.

The international pricing disparity that led to the signing of the most-favored-nation rule is profound. A 2020 report by the White House Council of Economic Advisers (CEA), which I chaired until recently, found large and increasing differences in drug prices here and abroad. For example, after adjusting for per capita GDP, Canada paid a mere 35 percent of the price in the United States for the 200 top-selling drugs. Switzerland’s per capita GDP in 2017 was actually 11 percent higher than that of the United States, yet the Swiss paid 39 percent of U.S. prices. Fifteen years ago, other developed countries were paying about half what Americans paid. Now it’s down to less than a third.

The fundamental source of the pricing disparity is very simple but poorly understood. Economic evidence abounds that reduced competition among sellers raises prices while reduced competition among buyers lowers them.

In the United States, there are, owing to government policies, adverse incentives for price competition among drug sellers, raising prices here. Overseas, there’s virtually zero competition among drug buyers — in most nations, a single-payer health-care system buys all drugs. This lower prices abroad.

Instead of adding government mandates to a problem caused by existing government policies both here and abroad, freeing up competition by deregulating the U.S. market and fighting for stronger trade enforcement would address the disparity more smartly — and more squarely sync with the president’s overall economic agenda.

Drug development is tremendously expensive. But by the time a drug gets to a foreign market, early costs are sunk. So, when a foreign government uses its clout to push the price of a drug down, it’s generally better for a drug company to accept that price than to walk away. It is better to make something than nothing. Moreover, small countries have no incentive to contribute to innovation by accepting higher prices, as their sales have a negligible impact on the worldwide revenues that drive innovation — and therefore have virtually no impact on the supply of new drugs coming into their counties.

This is, however, larceny on a global

Continue reading

Federal government no longer controlling key COVID-19 drug

Hospitals can order a coronavirus treatment directly from Gilead Sciences and its distributor instead of relying on the government as a go-between, the Trump administration announced Thursday, saying supply of the drug exceeds demand.

Remdesivir, sold under the brand name Veklury, and other therapies are being wielded against the coronavirus and will remain a key tool even after the approval of a vaccine.

The U.S. government bought up much of the drugmaker’s supply of remdesivir in June after clinical trials suggested it could help COVID-19 patients recover faster. Federal officials wanted to lock down the drug for Americans during the scramble to get the pandemic under control.

“Now, federal government oversight of the allocation of Veklury is not required because the drug is no longer a scarce resource—a tribute to progress we have made against COVID-19 and to the strength of our partnerships with the private sector,” Health and Human Services Secretary Alex Azar said.

Johanna Mercier, chief commercial officer at Gilead Sciences, said there is “enough supply on hand to treatment every existing COVID hospitalization in the U.S.”

She said they’re also confident they can meet demand even if the disease surges.

Though the Food and Drug Administration hasn’t fully approved a treatment for COVID-19, remdesivir is part of an expanding arsenal of drugs with emergency or temporary authorization for use on coronavirus patients.

A steroid, dexamethasone, has been shown to help some patients survive and — perhaps most exciting of all — companies are reporting positive results from trials involving synthetically produced proteins known as “monoclonal antibodies.”

Scientists say therapies will remain a key part of the response for the foreseeable future.

Efforts to inoculate the American public will stretch months into 2021 and the eventual vaccine will not be 100% protective, so doctors will rely on groundbreaking treatments to keep people out of the hospital or recover faster.

“There’s two issues — no vaccine works perfectly in everyone. Secondly, there will be some people who don’t end up getting the vaccine or are infected before they are able to get vaccinated,” said Dr. John Redd, HHS assistant health secretary for preparedness and response.

The administration made 500,000 doses of remdesivir available to states and territories between July and September.

Dr. Redd said localities and hospitals were not accepting or needing the full allocation made available to them, so the government no longer needed to be involved.

“We see this as a very good sign, and it’s been a key indicator that supply of remdesivir now outweighs demand,” Dr. Redd said.

Officials said AmerisourceBergen will remain the sole distributor of drug through the end of the year, and the price of the drug will not change. It will still be Gilead’s wholesale acquisition price — $3,2000 per treatment course, or $520 per vial.

Patients generally do not pay directly for drugs like remdesivir, since the costs are rolled into overall treatment costs paid by Medicare or private insurers.

Sign up for Daily Newsletters

Continue reading